Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2025

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients

J Dermatol Treat 2025;36:2562299 Doi: 10.1080/09546634.2025.2562299

Qiao Z,

Chai B,

Chen Y,

Jin HZ,

Yang B,

Li F,

Shi Y,

Gu J,

Guo Q,

Wu L,

Lu T,

Dang L,

Kang X,

Liu X

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

Keywords:

July 2022

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis

Front Med (Lausanne). 2022 doi: 10.3389/fmed.2022.859330

Hou Z,

Su X,

Han G,

Xue R,

Chen Y,

Wang H,

Yang B,

Liang Y,

Ji S

Promising results for patients with diffuse cutaneous systemic sclerosis (dcSSc) skin fibrosis and digital ulcers (DU), using JAK1/2 inhibitor baricitinib.